CD22 and Burkitt lymphoma: We conducted two single-arm clinical trials to explore the clinical efficacy and related toxicity of CD19/CD22 CAR T cell immunotherapy alone and in combination with ASCT in adult patients with r/r Burkitt lymphoma.